Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 22, 2019

Primary Completion Date

January 1, 2022

Study Completion Date

July 5, 2022

Conditions
In Vitro FertilizationIntracytoplasmic Sperm InjectionInfertility
Interventions
DRUG

Triptorelin acetate

0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.

DRUG

Cetrorelix

0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.

DRUG

recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin

Dosage adjustment according to the ovarian response.

DRUG

Human Chorionic Gonadotropin (hCG)

Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.

Trial Locations (1)

Unknown

Orient Hospital, Damascus

All Listed Sponsors
lead

Damascus University

OTHER

NCT04724343 - Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. | Biotech Hunter | Biotech Hunter